
Sanofi SA (NASDAQ:SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.
Sales increased 6% year over year, up 10.1% in constant currency, driven by growth in Immunology, pharmaceutical launches and Beyfortus.